E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Tonsillectomy and adenotonsillectomy
|
|
E.1.1.1 | Medical condition in easily understood language |
Operation to remove enlarged or frequently infected tonsils
|
|
E.1.1.2 | Therapeutic area | Diseases [C] - Ear, nose and throat diseases [C09] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Tonsillectomy is the commonest operation of childhood and results in considerable pain. Remifentanil is a potent, ultra short acting opiod with a long- established safety record in paediatric anaesthesia that is used to provide intraoperative analgesia. There is evidence from adult studies that remifentanil paradoxically increases postoperative pain, although this may be ablated if propofol (rather than inhalational anaesthesia) is used or if the remifentanil is tapered rather than abruptly discontinued at the end of surgery. The analgesic effect of gradual withdrawl of remifentanil at the end of surgery has not been studied in children and may have significant clinical implications. The primary measure of efficacy will be the dose of fentanyl rescue analgesia in the perioperative period (1 mcg.kg-1 bolus for >20% increase in pulse, blood pressure or movement intraoperatively or a FLACC(Face, Legs, Arms, Cry, Consolablity) score of >5 in the recovery unit. |
|
E.2.2 | Secondary objectives of the trial |
Secondary efficacy assessments will be a FLACC (Face, Legs, Arms, Cry, Consolablity) pain scores at 20, 40, 60, 90 and 120 minutes post- operatively based Sum of Pain Intensity Differences (SPID) analysis, and the Parents' Post Operative Pain Measure (PPOMP) on post- operative days 1,3,7,10,14,28. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
American Society Anaesthesiology I-II children 1 to 10 years Weight over 10.0 Kg Undergoing day case tonsillectomy or adentonsillectomy at Akershus Universitetssykehus, Lørenskog, Norway |
|
E.4 | Principal exclusion criteria |
Children who have had airway surgery previously. Children who have had any type of surgery in the previous 12 monhts. Children using chronic pain medication or who have used analgesia in the 24 hours preceeding surgery. Children who are known to suffer from NSAID sensitive asthma. Children with a known allergy to propofol or remifentanil. Pre-existing cardiac, renal, liver dysfunction. Children or parents who are not fluent in Norwegian or English. Children in whom more than three attempts at intravenous cannulation are required or in those who request an inhalational induction or premedication. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Intravenous fentanyl consumption in the perioperative period (mcg/kg). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
From the induction of anaesthesia until discharge from the day case surgical unit. |
|
E.5.2 | Secondary end point(s) |
a) Faces Legs Activity Cry Consolability (FLACC) pain scores at 20,40,60,90 and 120 minutes after the operation to give a Sum of Pain Intensity Differences (SPID). b) Parents' Post Operative Pain Measurement.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
From the cessation of anaesthesia until the 28th day following discharge from the day case surgical unit. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Completion of telephone follow up, 28 days after surgery of the last child included in the study.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |